BACKGROUND: Phosphate binders are widely used to control serum phosphorus levels in patients with chronic kidney disease (CKD). We analyzed the effects of phosphate binders …
3 bromate ion C carbon Ca calcium Ca2+ calcium ion CaCO3 calcium carbonate CaSO4 calcium sulfate Cd cadmium Ce cerium Ce3+ trivalent cerium ion Ce4+ tetravalent cerium …
MR Portillo, ME Rodríguez-Ortiz - Reviews in Endocrine and Metabolic …, 2017 - Springer
Uremic secondary hyperparathyroidism is a multifactorial and complex disease often present in advanced stages of chronic kidney disease. The accumulation of phosphate, the …
AJ Hutchison - Kidney international, 2009 - Elsevier
Hyperphosphatemia is an inevitable consequence of end-stage chronic kidney disease and is present in the majority of dialysis patients. Hyperphosphatemia is observationally and …
Hyperphosphataemia can be induced by three main conditions: a massive acute phosphate load, a primary increase in renal phosphate reabsorption, and an impaired renal phosphate …
C Zhang, J Wen, Z Li, J Fan - BMC nephrology, 2013 - Springer
Background Chronic kidney disease–mineral and bone disorder (CKD–MBD) is a common complication in CKD patients, particularly in those with end-stage renal disease that requires …
AJ Hutchison, ME Barnett, R Krause, JTC Kwan… - Nephron Clinical …, 2008 - karger.com
Abstract Background/Aims: Lanthanum carbonate (LC, FOSRENOL®) is an effective phosphate binder for which tolerability and a safety profile have been reported in …
AJ Hutchison, RJ Wilson, S Garafola, JB Copley - Nephrology, 2016 - Wiley Online Library
Despite 10 years of post‐marketing safety monitoring of the phosphate binder lanthanum carbonate, concerns about aluminium‐like accumulation and toxicity persist. Here, we …
AK Abu-Alfa - Advances in chronic kidney disease, 2011 - Elsevier
The strong association between nephrogenic systemic fibrosis (NSF) and exposure to gadolinium-based contrast agents (GBCAs) has greatly affected the care of patients with …